Nephro-Urology Monthly

Published by: Kowsar

Effects of Inactive Vitamin D on Persistent Secondary Hyperparathyroidism in Patients on Hemodialysis

Mojgan Jalalzadeh 1 , * and Nouraddin Mousavinasab 2
Authors Information
1 Department of Nephrology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Department of Biostatistics, Mazandaran University of Medical Sciences, Sari, IR Iran
Article information
  • Nephro-Urology Monthly: March 2017, 9 (2); e13156
  • Published Online: February 6, 2017
  • Article Type: Research Article
  • Received: December 24, 2016
  • Revised: January 21, 2017
  • Accepted: January 28, 2017
  • DOI: 10.5812/numonthly.45029

To Cite: Jalalzadeh M, Mousavinasab N. Effects of Inactive Vitamin D on Persistent Secondary Hyperparathyroidism in Patients on Hemodialysis, Nephro-Urol Mon. 2017 ; 9(2):e13156. doi: 10.5812/numonthly.45029.

Copyright © 2017, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Methods
3. Results
4. Discussion
  • 1. Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. : 209-16
  • 2. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008; 52(3): 519-30[DOI][PubMed]
  • 3. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008; 168(12): 1340-9[DOI][PubMed]
  • 4. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008; 168(11): 1174-80[DOI][PubMed]
  • 5. Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 2001; 59(3): 1187-201[DOI][PubMed]
  • 6. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8): 2208-18[DOI][PubMed]
  • 7. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005; 289(1)-28[DOI][PubMed]
  • 8. Birge SJ, Miller R. The role of phosphate in the action of vitamin D on the intestine. J Clin Invest. 1977; 60(5): 980-8[DOI][PubMed]
  • 9. Bailie GR, Massry SG, National Kidney F. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview. Pharmacotherapy. 2005; 25(12): 1687-707[DOI][PubMed]
  • 10. Eknoyan G, Levin NW. Impact of the new K/DOQI guidelines. Blood Purif. 2002; 20(1): 103-8[PubMed]
  • 11. Brown AJ, Slatopolsky E. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab. 2007; 3(2): 134-44[DOI][PubMed]
  • 12. Lips P, Wiersinga A, van Ginkel FC, Jongen MJ, Netelenbos JC, Hackeng WH, et al. The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab. 1988; 67(4): 644-50[DOI][PubMed]
  • 13. Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. : 752-8
  • 14. Naeem Z. Vitamin d deficiency- an ignored epidemic. Int J Health Sci (Qassim). 2010; 4(1)[PubMed]
  • 15. Melamed ML, Thadhani RI. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol. 2012; 7(2): 358-65[DOI][PubMed]
  • 16. Ko EJ, Kim BH, Jeong HY, Soe SU, Yang DH, Lee SY. Serum 25-hydroxyvitamin D as a predictor of hospitalization-free survival in predialysis and dialysis patients with chronic kidney disease: a single-center prospective observational analysis. Kidney Res Clin Pract. 2016; 35(1): 22-8[DOI][PubMed]
  • 17. Bansal B, Bansal S, Mithal A, Kher V, Marwaha R. Vitamin D deficiency in hemodialysis patients. Indian J Endocrinol Metab. 2012; 16(2): 270-3[DOI][PubMed]
  • 18. Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta JR. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007; 11(3): 315-21[DOI][PubMed]
  • 19. Diez GJR, Fassi J, Crucelequi S, Nuñez HR, Trillini M, Furci A, et al. 25-Hydroxy Vitamin D Levels in Hemodialysis-Requiring End-Stage Renal Disease Patients. Dialysis Transplant. 2008; 37(10): 388-90[DOI]
  • 20. Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T, et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant. 2008; 23(12): 4016-20[DOI][PubMed]
  • 21. Jean G, Souberbielle JC, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant. 2009; 24(12): 3799-805[DOI][PubMed]
  • 22. Fleet JC, Schoch RD. Molecular mechanisms for regulation of intestinal calcium absorption by vitamin D and other factors. Crit Rev Clin Lab Sci. 2010; 47(4): 181-95[DOI][PubMed]
  • 23. Bikle DD. Vitamin D and bone. Curr Osteoporos Rep. 2012; 10(2): 151-9[DOI][PubMed]
  • 24. Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2008; 23(7): 2311-8[DOI][PubMed]
  • 25. Taskapan H, Wei M, Oreopoulos DG. 25(OH) vitamin D3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol. 2006; 38(2): 323-9[DOI][PubMed]
  • 26. DeVille J, Thorp ML, Tobin L, Gray E, Johnson ES, Smith DH. Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology (Carlton). 2006; 11(6): 555-9[DOI][PubMed]
  • 27. Jean G, Souberbielle JC, Lechevallier S, Chazot C. Kinetics of serum 25-hydroxyvitamin D in haemodialysis patients treated with monthly oral cholecalciferol. Clin Kidney J. 2015; 8(4): 388-92[DOI][PubMed]
  • 28. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004; 24(5): 503-10[DOI][PubMed]
  • 29. McClellan WM, Ramirez SP, Jurkovitz C. Screening for chronic kidney disease: unresolved issues. J Am Soc Nephrol. 2003; 14(7 Suppl 2)-7[PubMed]
  • 30. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17): 2038-47[DOI][PubMed]
  • 31. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005; 45(6): 1026-33[PubMed]
  • 32. Andress DL. Vitamin d in health and disease: Vitamin D treatment in chronic kidney disease. : 315-21
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments